Foundation / Corporation
09/19/18 8:00 PM EST
Grants to USA, Canada, and International researchers for studies on novel interventions and treatments for individuals with autism spectrum disorder. Letters of intent are due July 18, 2018. Treatments may include medical approaches such as pharmacological treatments and complementary and alternative forms of healthcare, as well as behavioral and/or psychosocial interventions.
Autism Speaks invites Treatment Research Grant applications to conduct innovative studies of novel treatments and interventions for people with autism spectrum disorder (ASD) throughout the life span. Successful applications will focus on evaluation of the efficacy, effectiveness or other therapeutic benefits of the targeted intervention.
The Treatment Research Grant award mechanism directly addresses Goal #3 in the Autism Speaks Science Strategic Plan for 2018-2020: Facilitate the clinical testing of promising life-enhancing interventions. Specifically, this mechanism focuses on efficacy or comparative effectiveness research using rigorous methodologies. The expectation is that funded investigations will produce evidence that guides future practice or key results that motivate future large-scale investigations. Safety and cost-effectiveness can, and often should, be included elements but should not be the sole or primary focus of the study. Open-label or purely observational studies are not recommended. Animal model pre-clinical studies will not be considered for this mechanism.
Successful applications will include consideration of one or more of the following priorities in the aims, design and/or implementation of the study:
1. Inclusion of cognitively impaired individuals with ASD.
2. Inclusion of validation sensitive, objective, quantitative outcome measures and/or biomarkers as secondary outcomes that can be measured longitudinally.
3. Focus on one or more of the common, co-occurring medical or behavioral conditions that reduce quality of life in autism – either as a primary or secondary outcome measure (in addition to core autism symptoms).
4. Focus on an intervention with potential to improve the transition to adulthood and/or the health and well-being of adults with ASD.
Note: Successful applications are not expected to include all elements.
Additionally, Treatment Research Grants must satisfy the following requirements:
- Build on existing feasibility, safety and/or efficacy data to further investigate biomedical or behavioral treatment approaches.
- Be supported by promising results in previous research, by a body of existing research evidence and/or by a strong theoretical justification.
- Come from established investigators with demonstrated potential for and a commitment to biomedical research in autism or related developmental disabilities.
GrantWatch ID#: 127317
This program anticipates granting two awards at $250,000 per year with a maximum of $750,000 per award.
This program anticipates granting awards for up to three years.
Investigators holding full-time faculty appointments, professional affiliations or equivalent at accredited academic, medical, research, or educational institutions are eligible to apply.
Postdoctoral fellows who have a strong team and can show proof of a full-time faculty appointment by the expected grant start, are also eligible.
Applications will not be accepted from individuals or proprietary organizations to support the research and development of products or treatments for profit. Principal Investigator or Co-Investigator applicants are restricted to one submission per RFA. Multiple submissions will be withdrawn.
Submission, Review and Notification Schedule (subject to change):
- Letter of intent due: July 18, 2018, 8 pm Eastern Time
- Letter of intent notifications: Early August
- Applications due: September 19, 2018, 8 pm Eastern Time
- Peer review panels: October/November 2018
- Notifications: Late December 2018
- Earliest grant start date: February 2019
LOIs will be subject to in-depth review. After all LOIs are reviewed, Autism Speaks will send an email indicating approval or disapproval. Please do not contact the grants staff regarding LOI acceptability. Applicants with approved LOIs will be permitted to submit a full application. All decisions are final.
More information: https://www.autismspeaks.org/science/science-news/autism-speaks-launches-15-million-funding-opportunity-treatment-studies/
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
Apply online: https://science.grants.autismspeaks.org/
For grants administration/online application/budget questions:
Joan New, MBA, Grants Manager
For application development questions:
Thomas W. Frazier, PhD, Chief Science Officer
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.